Lauren White - 21 Jun 2021 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Financial Officer
Signature
/s/ Shoaib Ghias, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
21 Jun 2021
Net transactions value
$0
Form type
4
Filing time
21 Jun 2021, 20:22:40 UTC
Next filing
16 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Award $0 +136,000 $0.000000 136,000 21 Jun 2021 Common Stock 136,000 $38.49 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on June 21, 2022, with the remainder vesting in 36 equal monthly installments thereafter.